688321 微芯生物
已收盘 11-20 15:00:01
资讯
新帖
简况
微芯生物：拟向特定对象增发募资不超过9.6亿元
每日经济新闻 · 11-20 19:29
微芯生物：拟向特定对象增发募资不超过9.6亿元
微芯生物：拟定增募资不超9.6亿元
美港电讯 · 11-20 19:16
微芯生物：拟定增募资不超9.6亿元
微芯生物最新公告：拟定增募资不超过9.6亿元
证券之星 · 11-20 19:10
微芯生物最新公告：拟定增募资不超过9.6亿元
微芯生物(688321.SH)拟定增募资不超9.6亿元 用于创新药研发项目等
智通财经 · 11-20 19:07
微芯生物(688321.SH)拟定增募资不超9.6亿元 用于创新药研发项目等
微芯生物：厚积薄发 收入增长在前方
财通证券 · 11-19 00:00
微芯生物：厚积薄发 收入增长在前方
【机构调研记录】鹏华基金调研华锐精密、微芯生物等7只个股（附名单）
证券之星 · 11-18 08:02
【机构调研记录】鹏华基金调研华锐精密、微芯生物等7只个股（附名单）
【机构调研记录】长信基金调研微芯生物、国芯科技等4只个股（附名单）
证券之星 · 11-18 08:02
【机构调研记录】长信基金调研微芯生物、国芯科技等4只个股（附名单）
【机构调研记录】广发基金调研微芯生物、中科蓝讯等5只个股（附名单）
证券之星 · 11-18 08:02
【机构调研记录】广发基金调研微芯生物、中科蓝讯等5只个股（附名单）
【机构调研记录】太平基金调研微芯生物、江苏新能等5只个股（附名单）
证券之星 · 11-18 08:01
【机构调研记录】太平基金调研微芯生物、江苏新能等5只个股（附名单）
【机构调研记录】安信基金调研微芯生物、焦点科技等3只个股（附名单）
证券之星 · 11-18 08:01
【机构调研记录】安信基金调研微芯生物、焦点科技等3只个股（附名单）
微芯生物大跌5.21% 3家券商给予增持建议
智选洞察 · 11-15
微芯生物大跌5.21% 3家券商给予增持建议
微芯生物11月12日获主力加仓4398万元 环比增加1224.70%
市场透视 · 11-12
微芯生物11月12日获主力加仓4398万元 环比增加1224.70%
微芯生物创1年新高 生物医药产业蓬勃发展
智选洞察 · 11-12
微芯生物创1年新高 生物医药产业蓬勃发展
太平洋：给予微芯生物买入评级
证券之星 · 11-04
太平洋：给予微芯生物买入评级
太平洋给予微芯生物买入评级，微芯生物：核心产品快速增长，西格列他钠MASH数据积极
每日经济新闻 · 11-04
太平洋给予微芯生物买入评级，微芯生物：核心产品快速增长，西格列他钠MASH数据积极
微芯生物大幅上涨 获主力净流入45万元
智选洞察 · 11-04
微芯生物大幅上涨 获主力净流入45万元
微芯生物：10月31日进行路演，包括知名机构上海保银投资的多家机构参与
证券之星 · 11-04
微芯生物：10月31日进行路演，包括知名机构上海保银投资的多家机构参与
【私募调研记录】保银投资调研微芯生物
证券之星 · 11-04
【私募调研记录】保银投资调研微芯生物
微芯生物(688321.SH)：西奥罗尼胶囊一线治疗广泛期小细胞肺癌临床试验获批
智通财经 · 11-01
微芯生物(688321.SH)：西奥罗尼胶囊一线治疗广泛期小细胞肺癌临床试验获批
微芯生物：获得《药物临床试验批准通知书》
每日经济新闻 · 11-01
微芯生物：获得《药物临床试验批准通知书》
加载更多
公司概况
公司名称：
深圳微芯生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2019-08-12
主营业务：
深圳微芯生物科技股份有限公司的主营业务为药物技术开发、相关成果商业应用，主要产品均为自主研究发现与开发的新分子实体且作用机制新颖的原创新药。公司获得2020中国医药工业信息中心颁发的“中国医药新锐创新力量”奖；2020年10月，公司获 得“2020中国化学制药行业成长型优秀企业品牌”与“2020中国化学制药行业抗肿瘤和免疫调节剂类优秀产品品牌”两个奖项。
发行价格：
20.43
{"stockData":{"symbol":"688321","market":"SH","secType":"STK","nameCN":"微芯生物","latestPrice":22.97,"timestamp":1732086001000,"preClose":22.42,"halted":0,"volume":4602097,"delay":0,"floatShares":408000000,"shares":408000000,"eps":-0.1725,"marketStatus":"已收盘","marketStatusCode":5,"change":0.55,"latestTime":"11-20 15:00:01","open":22.5,"high":23.18,"low":22.33,"amount":105000000,"amplitude":0.0379,"askPrice":22.97,"askSize":8,"bidPrice":22.95,"bidSize":10,"shortable":0,"etf":0,"ttmEps":-0.1725,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732152600000},"adr":0,"adjPreClose":22.42,"symbolType":"stock_kcb","openAndCloseTimeList":[[1732066200000,1732073400000],[1732078800000,1732086000000]],"highLimit":24.66,"lowLimit":20.18,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407795845,"pbRate":6.16,"roa":"--","roe":"--","epsLYR":0.2176,"committee":-0.390977,"marketValue":9367000000,"floatMarketCap":9367000000,"peRate":-133.159421,"changeRate":0.0245,"turnoverRate":0.0113,"status":0,"afterMarket":{"amount":0,"volume":0,"close":22.97,"buyVolume":0,"sellVolume":0,"time":1732088039464,"indexStatus":"已收盘 11-20 15:30:00","preClose":22.42}},"requestUrl":"/m/hq/s/688321","defaultTab":"news","newsList":[{"id":"2484540191","title":"微芯生物：拟向特定对象增发募资不超过9.6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484540191","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484540191?lang=zh_cn&edition=full","pubTime":"2024-11-20 19:29","pubTimestamp":1732102140,"startTime":"0","endTime":"0","summary":"每经AI快讯，微芯生物11月20日晚间发布公告称，本次向特定对象发行股票相关事项已于2024年11月20日经公司第三届董事会第八次会议审议通过。本次发行拟募集不超过9.6亿元，募集资金用于以下用途：创新药研发项目，总投资约7.46亿元，拟投入募集资金7.1亿元；补充流动资金项目，总投资2.5亿元，拟投入募集资金2.5亿元。微芯生物的总经理、董事长均是XIANPING LU，男，61岁，学历背景为博士。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120192928abd1d6a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120192928abd1d6a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2484999881","title":"微芯生物：拟定增募资不超9.6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484999881","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484999881?lang=zh_cn&edition=full","pubTime":"2024-11-20 19:16","pubTimestamp":1732101392,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159992","688321","BK1161","BK1574","BK0239","06978"],"gpt_icon":0},{"id":"2484775199","title":"微芯生物最新公告：拟定增募资不超过9.6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484775199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484775199?lang=zh_cn&edition=full","pubTime":"2024-11-20 19:10","pubTimestamp":1732101005,"startTime":"0","endTime":"0","summary":"微芯生物公告，公司拟向特定对象发行股票拟募集资金总额不超过9.6亿元，募集资金总额扣除相关发行费用后的净额将用于投资创新药研发项目和补充流动资金。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000032684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2484196420","title":"微芯生物(688321.SH)拟定增募资不超9.6亿元 用于创新药研发项目等","url":"https://stock-news.laohu8.com/highlight/detail?id=2484196420","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484196420?lang=zh_cn&edition=full","pubTime":"2024-11-20 19:07","pubTimestamp":1732100871,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物(688321.SH)发布公告，公司拟向特定对象发行股票，募集资金总额不超过9.6亿元(含本数)，募集资金总额扣除相关发行费用后的净额将用于投资：创新药研发项目、补充流动资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0239","159992","06978","BK1161","688321"],"gpt_icon":0},{"id":"2484943870","title":"微芯生物：厚积薄发 收入增长在前方","url":"https://stock-news.laohu8.com/highlight/detail?id=2484943870","media":"财通证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484943870?lang=zh_cn&edition=full","pubTime":"2024-11-19 00:00","pubTimestamp":1731945600,"startTime":"0","endTime":"0","summary":"而MSS/pMMR 结直肠癌、小细胞肺癌以及胰腺癌目前的治疗均尚属空白，竞品少。公司产品已在部分适应症中取得突破性进展，小细胞肺癌和胰腺癌的治疗也有取得突破性进展的潜力。目前该三药联合疗法已被2024 年CSCO 诊疗指南收录，西达本胺也被国家药监局纳入“突破性治疗品种”。目前治疗以放化疗为主，大多数SCLC 患者易出现复发和耐药。西奥罗尼II 期临床三线治疗小细胞肺癌ORR 为17.9%，DCR 为64.3%。截至目前，已转股0.02%，暂不向下修订转股价格。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111920212895be4a53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111920212895be4a53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2484633526","title":"【机构调研记录】鹏华基金调研华锐精密、微芯生物等7只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2484633526","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484633526?lang=zh_cn&edition=full","pubTime":"2024-11-18 08:02","pubTimestamp":1731888151,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月15日披露的机构调研信息，鹏华基金近期对7家上市公司进行了调研，相关名单如下：1）华锐精密 个股亮点：华锐转债于2022-07-21上市；公司的主营业务为硬质合金数控刀片的研发、生产和销售业务。；公司与特斯拉、华为有业务往来4）灿勤科技 个股亮点：公司的主要产品在华为5G基站中占据较高市场份额。旗下最近一年表现最佳的公募基金产品为港美互联网LOF，最新单位净值为1.3，近一年增长29.81%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800001158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","688059","BK0256","BK0239"],"gpt_icon":0},{"id":"2484663334","title":"【机构调研记录】长信基金调研微芯生物、国芯科技等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2484663334","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484663334?lang=zh_cn&edition=full","pubTime":"2024-11-18 08:02","pubTimestamp":1731888149,"startTime":"0","endTime":"0","summary":"3）英派斯 个股亮点：公司专注于健身器材的研发制造及销售,可提供健身器材全套解决方案。主要产品有跑步机、椭圆机、健身车、动感单车、划船机等有氧器材,单功能、多功能力量训练器械等。旗下最近一年表现最佳的公募基金产品为长信标普100等权重指数人民币，最新单位净值为2.17，近一年增长26.7%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800001155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321","BK0231","688262"],"gpt_icon":0},{"id":"2484663378","title":"【机构调研记录】广发基金调研微芯生物、中科蓝讯等5只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2484663378","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484663378?lang=zh_cn&edition=full","pubTime":"2024-11-18 08:02","pubTimestamp":1731888122,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月15日披露的机构调研信息，广发基金近期对5家上市公司进行了调研，相关名单如下：1）微芯生物 个股亮点：微芯转债于2022-07-28上市；公司为患者提供可承受的、临床亟需的原创新分子实体药物2）中科蓝讯 个股亮点：公司主营业务为无线音频SoC芯片的研发、设计与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800001119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0214","BK0239","688332","688321"],"gpt_icon":0},{"id":"2484666330","title":"【机构调研记录】太平基金调研微芯生物、江苏新能等5只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2484666330","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484666330?lang=zh_cn&edition=full","pubTime":"2024-11-18 08:01","pubTimestamp":1731888115,"startTime":"0","endTime":"0","summary":"；公司已多次收到先进封装清洗设备的采购订单，及电镀设备的批量订单。太平基金成立于2013年，截至目前，资产管理规模562.51亿元，排名78/208；资产管理规模488.33亿元，排名74/208；管理公募基金数61只，排名84/208；旗下公募基金经理20人，排名67/208。旗下最近一年表现最佳的公募基金产品为太平行业优选股票A，最新单位净值为0.82，近一年增长29.76%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800001113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603693","BK0271","BK0239","688321"],"gpt_icon":0},{"id":"2484466334","title":"【机构调研记录】安信基金调研微芯生物、焦点科技等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2484466334","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484466334?lang=zh_cn&edition=full","pubTime":"2024-11-18 08:01","pubTimestamp":1731888115,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为安信中证一带一路主题指数，最新单位净值为1.75，近一年增长19.64%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800001112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0091","BK0186","BK0137","BK0217","BK0028","BK0107","BK0132","BK0108","002315","BK0070","BK0239","688321"],"gpt_icon":0},{"id":"2483115263","title":"微芯生物大跌5.21% 3家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483115263","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483115263?lang=zh_cn&edition=full","pubTime":"2024-11-15 14:49","pubTimestamp":1731653343,"startTime":"0","endTime":"0","summary":"11月15日，微芯生物股价大幅下跌，截至14点49分，微芯生物下跌5.21%，报22.58元/股，成交1.60亿元，换手率1.69%。此外，数据统计显示，近半年内3家券商给予增持建议，6家券商给予买入建议。资金动向截止发稿，微芯生物获得主力净流出2218万元，其中超大单流出2046万元，大单流出171万元。最新财报显示，今年三季报，微芯生物实现营业收入4.81亿元，同比增长38.02%，净利润为-5,108.49万元，同比减少147.26%，基本每股收益为-0.13元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115144929a239f741&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115144929a239f741&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2482289721","title":"微芯生物11月12日获主力加仓4398万元 环比增加1224.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482289721","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482289721?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:22","pubTimestamp":1731396135,"startTime":"0","endTime":"0","summary":"11月12日, 微芯生物股价涨1.22%，报收24.93元，成交金额3.01亿元，换手率2.92%，振幅6.25%，量比2.02。微芯生物今日主力资金净流入4398万元，上一交易日主力净流入332万元，今日环比增加1224.70%。|11月12日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|我爱我家|6.56%|#|联盛化学|6.47%|#|大众交通|6.42%|#|长药控股|6.32%|#|药易购|5.45%|#|联合化学|5.03%|#|欧菲光|4.91%|#|黑芝麻|4.74%|#|雄帝科技|4.56%|#|盛天网络|4.19%|微芯生物所在的化学制药行业，今日主力净流入5.41亿元，行业排名9/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112155704abb91978&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112155704abb91978&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2482715866","title":"微芯生物创1年新高 生物医药产业蓬勃发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2482715866","media":"智选洞察","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482715866?lang=zh_cn&edition=full","pubTime":"2024-11-12 10:15","pubTimestamp":1731377728,"startTime":"0","endTime":"0","summary":"11月12日，微芯生物股价大幅上涨，截至10点15分，微芯生物上涨5.08%，报25.88元/股，创近1年新高，成交1.41亿元，换手率1.37%，振幅5.81%。资金动向截止发稿，微芯生物获得主力净流入3414万元，其中超大单流入3600万元，大单流出186万元。主营业务及业绩微芯生物公司主营业务为为患者提供可承受的、临床亟需的原创新分子实体药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112101554a22e2da9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112101554a22e2da9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["399441","161726","688321","BK0239"],"gpt_icon":0},{"id":"2480342605","title":"太平洋：给予微芯生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480342605","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480342605?lang=zh_cn&edition=full","pubTime":"2024-11-04 11:54","pubTimestamp":1730692499,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司谭紫媚,张懿近期对微芯生物进行研究并发布了研究报告《微芯生物：核心产品快速增长，西格列他钠MASH数据积极》，本报告对微芯生物给出买入评级，当前股价为22.97元。 西格列他钠前三季度销量同比增长322.98%，收入同比增长414.65%。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为31.71。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400011408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","688321"],"gpt_icon":0},{"id":"2480038345","title":"太平洋给予微芯生物买入评级，微芯生物：核心产品快速增长，西格列他钠MASH数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2480038345","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480038345?lang=zh_cn&edition=full","pubTime":"2024-11-04 10:14","pubTimestamp":1730686447,"startTime":"0","endTime":"0","summary":"太平洋11月04日发布研报称，给予微芯生物（688321.SH，最新价：23.2元）买入评级。评级理由主要包括：1）核心产品拓展新适应症，助力营收高速增长；2）西格列他钠MASHII期数据积极，入选美国肝病年会口头报告；3）期间费用率下降，毛利率基本稳定。风险提示：创新药研发不及预期风险；新产品放量不及预期风险；医保支付政策调整带来的风险；地缘政治风险。AI点评：微芯生物近一个月获得1份券商研报关注，买入1家。文章来源：每日经济新闻原标题：太平洋给予微芯生物买入评级，微芯生物：核心产品快速增长，西格列他钠MASH数据积极","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104102914ab9c616b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104102914ab9c616b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["601099","688321"],"gpt_icon":0},{"id":"2480348429","title":"微芯生物大幅上涨 获主力净流入45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480348429","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480348429?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:44","pubTimestamp":1730684671,"startTime":"0","endTime":"0","summary":"11月04日，微芯生物股价大幅上涨，截至09点44分，微芯生物上涨5.01%，报23.48元/股，成交4183万元，换手率0.44%。资金动向截止发稿，微芯生物获得主力净流入45万元，其中超大单流入144万元，大单流出98万元。主营业务及业绩微芯生物公司主营业务为为患者提供可承受的、临床亟需的原创新分子实体药物。最新财报显示，今年三季报，微芯生物实现营业收入4.81亿元，同比增长38.02%，净利润为-5,108.49万元，同比减少147.26%，基本每股收益为-0.13元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104095203a212cc63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104095203a212cc63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2480310557","title":"微芯生物：10月31日进行路演，包括知名机构上海保银投资的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2480310557","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480310557?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:33","pubTimestamp":1730683997,"startTime":"0","endTime":"0","summary":"公司目前正在积极筹备MSH适应症国内的III期临床，并在寻找海外合作伙伴。这也是目前国际主流的MSH临床检测方法，一致性得到广泛认可。肝脏脂肪下降方面，目前公认指标是MRI-PDFF下降≥30%患者的比例。THR-β的III期临床中，100mg用药523周剔除安慰剂效应LSM下降0.5kP。该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为31.71。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400003176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2480319577","title":"【私募调研记录】保银投资调研微芯生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2480319577","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480319577?lang=zh_cn&edition=full","pubTime":"2024-11-04 08:00","pubTimestamp":1730678442,"startTime":"0","endTime":"0","summary":"我们拥有二十六位专业人员来负责投资组合管理、研究、交易、风险管理及运营。通过深入的研究和分析，Pinpoint将致力于打造一个业内排名位于前列，具有出色资产管理能力的资产管理机构。证券之星点评：保银投资在2021年证券之星私募顶投榜中排名第3位，拥有王强,李墨等知名基金经理。本次调研的上市公司平均市盈率-129.65。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2024110400001402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2480724500","title":"微芯生物(688321.SH)：西奥罗尼胶囊一线治疗广泛期小细胞肺癌临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2480724500","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480724500?lang=zh_cn&edition=full","pubTime":"2024-11-01 17:41","pubTimestamp":1730454113,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物(688321.SH)发布公告，公司及全资子公司成都微芯药业有限公司近日收到国家药品监督管理局签发的境内生产药品注册临床试验的《药物临床试验批准通知书》，同意公司西奥罗尼胶囊联合PD-(L)1单抗及化疗在广泛期小细胞肺癌一线治疗患者中开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1205697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","03347","BK1141","BK0239","BK1576","688321"],"gpt_icon":0},{"id":"2480072136","title":"微芯生物：获得《药物临床试验批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2480072136","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480072136?lang=zh_cn&edition=full","pubTime":"2024-11-01 17:36","pubTimestamp":1730453778,"startTime":"0","endTime":"0","summary":"2023年1至12月份，微芯生物的营业收入构成为：医药制造业占比98.83%。微芯生物的董事长、总经理均是XIANPING LU，男，61岁，学历背景为博士。截至发稿，微芯生物市值为91亿元。道达号“个股趋势”提醒：1. 近30日内无机构对微芯生物进行调研。每经头条——一次暂停，就停了13年！中国两大巨头“拆高墙”：你的客户，也可以是我的客户","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101173723ab9181d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101173723ab9181d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2019-08-12","address":"广东省深圳市南山区西丽街道曙光社区智谷产业园B栋21F-24F","stockEarnings":[{"period":"1week","weight":-0.0598},{"period":"1month","weight":0.0314},{"period":"3month","weight":0.3544},{"period":"6month","weight":0.0759},{"period":"1year","weight":-0.0449},{"period":"ytd","weight":0.0465}],"companyName":"深圳微芯生物科技股份有限公司","boardCode":"AI0027","perCapita":"21923股","boardName":"医药制造业","registeredCapital":"40779万元","compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":0.0306},{"period":"3month","weight":0.1823},{"period":"6month","weight":0.0904},{"period":"1year","weight":0.0978},{"period":"ytd","weight":0.1321}],"survey":" 深圳微芯生物科技股份有限公司的主营业务为药物技术开发、相关成果商业应用，主要产品均为自主研究发现与开发的新分子实体且作用机制新颖的原创新药。公司获得2020中国医药工业信息中心颁发的“中国医药新锐创新力量”奖；2020年10月，公司获 得“2020中国化学制药行业成长型优秀企业品牌”与“2020中国化学制药行业抗肿瘤和免疫调节剂类优秀产品品牌”两个奖项。","serverTime":1732124379199,"listedPrice":20.43,"stockholders":"18601人(较上一季度减少4.63%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"微芯生物,688321,微芯生物股票,微芯生物股票老虎,微芯生物股票老虎国际,微芯生物行情,微芯生物股票行情,微芯生物股价,微芯生物股市,微芯生物股票价格,微芯生物股票交易,微芯生物股票购买,微芯生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}